Allergy and Rhinology

Aims & Scope

Therapeutic Advances in Allergy and Rhinology is a leading, open access, peer reviewed, medical specialty journal in press since 2010.

Its aim is to provide a platform for original research, clinical trials, review articles and case reports within an Open Access platform.

Therapeutic Advances in Allergy and Rhinology publishes articles ranging in topics from surgical techniques to diagnostic dilemmas, as well as treatment options and pathophysiologic investigations in sinonasal diseases, asthma and other allergic disorders.

Metrics & Ranking

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Directory of Open Access Journals (DOAJ)
• Web of Science

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.

• Aims scope
• Homepage
• Oa statement
• Author instructions
• License terms
• Review url
• Board url
• Plagiarism url
• Preservation url
• Apc url
• License

Plagiarism Policy

This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.

For more details, please refer to our official: Plagiarism Policy.

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Commentary on Gender Differences in Prevalence, Treatment, and Quality of Life of Patients with Chronic Rhinosinusitis

  Citation: 61

  Authors: Elisabeth H., Bruce K., Kathryn E., Rakesh K., Sean B., Robert C., David B., Stephanie Shintani

• Contemporary Assessment of the Disease Burden of Sinusitis

  Citation: 56

  Authors: Neil

• Very Low Dose Bevacizumab for the Treatment of Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia

  Citation: 48

  Authors: Andrew B., Douglas A., Paul, Jaszmin, Nancy, Sara L.

• Validation of a Grading System for Lateral Nasal Wall Insufficiency

  Citation: 44

  Authors: Gabriel J., Natalia, Sam P.

• Efficacy of Medical Therapy in Treatment of Chronic Rhinosinusitis

  Citation: 42

  Authors: Lee C., Nicholas W., Lifeng, Richard G.

• Fractional Exhaled Nitric Oxide (FeNo) in Different Asthma Phenotypes

  Citation: 41

  Authors: Bilun, Benan, Ismail, Kasim

• Allergen-Specific Immunoglobulin E and Allergic Rhinitis Severity

  Citation: 40

  Authors: Angelo G., Mara, Vanessa, Vania, Maria Chiara, Arianna, Gian Luigi, Giorgio

• Group 10 Allergens (Tropomyosins) from House-Dust Mites May Cause Covariation of Sensitization to Allergens from Other Invertebrates

  Citation: 38

  Authors: Rubaba Hamid, Muhammad, Muhammad, Farhana Riaz

• Immunotherapy in Allergic Fungal Sinusitis: The Controversy Continues. A Recent Review of Literature

  Citation: 33

  Authors: Mary S., Gregory R., Erik Kent, Erika Gonzalez

• Immunoglobulin G4-related Sclerosing Disease of the Paranasal Sinuses: A Case Report and Literature Review

  Citation: 29

  Authors: Nathan D., Ian M.